Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly crawled date : 2022 - 05 - 11 save search
FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant
FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant covid
The PCSK9 Inhibitors Market to Grow Rapidly During the Forecast Period with a CAGR of 15.1%, Analyzes DelveInsight
Published: 2022-05-11 (Crawled : 15:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
market
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Published: 2022-05-11 (Crawled : 12:20) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
biopharma disease
Heart Failure Treatment Offers Hope to Diabetics
Published: 2022-05-11 (Crawled : 12:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -2.55%
H: 2.32%
C: -0.85%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
treatment heart
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
Published: 2022-05-11 (Crawled : 11:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 2.48%
H: 1.15%
C: -2.43%
covid-19 olumiant treatment fda
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.